The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620607
Title:
The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.
Authors:
Halpin, David M
Abstract:
Bronchodilator therapy is central to the management of chronic obstructive pulmonary disease and are recommended as the preferred treatment by the Global Obstructive Lung Disease Initiative (GOLD). Long acting anti-muscarinics (LAMA) and long acting β₂ agonists (LABA) are both more effective than regular short-acting drugs but many patients remain symptomatic despite monotherapy with these drugs. Combination therapy with LAMA and LABA increases the therapeutic benefit while minimizing dose-dependent side effects of long-acting bronchodilator therapy. The TOviTO programme has investigated the benefits of treatment with a combination of tiotropium and olodaterol administered via a single inhaler. Tiotropium+olodaterol 5/5 μg significantly improved forced expiratory volume in 1 second (FEV₁) area under the curve from 0 to 3 hours, trough FEV₁ health status and breathlessness versus the mono-components and placebo. Tiotropium+olodaterol 5/5 μg also increased endurance time and reduced dynamic hyperinflation during constant work rate cycle ergometry. On the basis of these and other studies the 2017 GOLD report recommends escalating to dual bronchodilator therapy in patients in groups B and C if they remain symptomatic or continue to have exacerbations and as initial therapy for patients in group D.
Citation:
The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease. 2018, 81 (1):13-18 Tuberc Respir Dis (Seoul)
Publisher:
Tuberculosis & Respiratory Diseases
Journal:
Tuberculosis and respiratory diseases
Issue Date:
Jan-2018
URI:
http://hdl.handle.net/11287/620607
DOI:
10.4046/trd.2017.0098
PubMed ID:
29332320
Additional Links:
https://www.e-trd.org/DOIx.php?id=10.4046/trd.2017.0098
Note:
This article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.
Type:
Journal Article
Language:
en
ISSN:
1738-3536
Appears in Collections:
Respiratory Medicine; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHalpin, David Men
dc.date.accessioned2018-02-08T15:26:41Z-
dc.date.available2018-02-08T15:26:41Z-
dc.date.issued2018-01-
dc.identifier.citationThe Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease. 2018, 81 (1):13-18 Tuberc Respir Dis (Seoul)en
dc.identifier.issn1738-3536-
dc.identifier.pmid29332320-
dc.identifier.doi10.4046/trd.2017.0098-
dc.identifier.urihttp://hdl.handle.net/11287/620607-
dc.description.abstractBronchodilator therapy is central to the management of chronic obstructive pulmonary disease and are recommended as the preferred treatment by the Global Obstructive Lung Disease Initiative (GOLD). Long acting anti-muscarinics (LAMA) and long acting β₂ agonists (LABA) are both more effective than regular short-acting drugs but many patients remain symptomatic despite monotherapy with these drugs. Combination therapy with LAMA and LABA increases the therapeutic benefit while minimizing dose-dependent side effects of long-acting bronchodilator therapy. The TOviTO programme has investigated the benefits of treatment with a combination of tiotropium and olodaterol administered via a single inhaler. Tiotropium+olodaterol 5/5 μg significantly improved forced expiratory volume in 1 second (FEV₁) area under the curve from 0 to 3 hours, trough FEV₁ health status and breathlessness versus the mono-components and placebo. Tiotropium+olodaterol 5/5 μg also increased endurance time and reduced dynamic hyperinflation during constant work rate cycle ergometry. On the basis of these and other studies the 2017 GOLD report recommends escalating to dual bronchodilator therapy in patients in groups B and C if they remain symptomatic or continue to have exacerbations and as initial therapy for patients in group D.en
dc.language.isoenen
dc.publisherTuberculosis & Respiratory Diseasesen
dc.relation.urlhttps://www.e-trd.org/DOIx.php?id=10.4046/trd.2017.0098en
dc.rightsArchived with thanks to Tuberculosis and respiratory diseases. Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).en
dc.subjectWessex Classification Subject Headings::Respiratory medicineen
dc.titleThe Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.en
dc.typeJournal Articleen
dc.identifier.journalTuberculosis and respiratory diseasesen
dc.description.noteThis article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.en
dc.type.versionPublisheden
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.